Search - tctmd.com

Displaying 1 - 20 of 53

Sort: Relevancy | Date

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

News Conference News PCR London Valves 2016

Leaflet Restriction After TAVR: Two Hospitals Tracking Patients Find Similar Rates of the Phenomenon

Shelley Wood

September 20, 2016

News Industry News

Micell Technologies Highlights Data From Published Propensity Analysis of MiStent SES® and Market Standard Xience V® Coronary Stent

February 24, 2016

News Features

Increased Early Risk of Stent Thrombosis With the Absorb Bioresorbable Scaffold

Michael O'Riordan

January 06, 2016

News Daily News

Residual Dissection After DCB Treatment for De Novo CAD Generally Resolves

Caitlin E. Cox

November 26, 2015

Presentation TCT 2015

ISAR-DESIRE 4: A Prospective Randomized Trial of Plaque Modification With a Scoring Balloon During Drug-Coated Balloon Treatment of Coronary In-Stent Restenosis

Presenter: Cindy L. Grines, Robert A. Byrne

October 14, 2015

Presentation TCT 2015

ISAR-DESIRE 4: A Prospective Randomized Trial of Plaque Modification With a Scoring Balloon During Drug-Coated Balloon Treatment of Coronary In-Stent Restenosis

Presenter: Robert A. Byrne

October 14, 2015

News Industry News

Plaque Modification With Scoring Balloon Improves Angiographic Outcomes In Patients Treated With A Drug-Coated Balloon For Drug-Eluting Stent Restenosis

October 14, 2015

News Conference News TCT 2015

ISAR-DESIRE 4: Scoring Balloon Predilation Effective at 1 Year in Patients With DES Restenosis

October 14, 2015

Presentation TCT 2015

Case Presentation Before Second-Time Treatment: Recurrent DES Restenosis

Presenter: Robert A. Byrne, Stefan K. James, Wojtek Wojakowski

October 11, 2015

$The Resurrection of Historic Therapies for Refractory Restenosis: Vascular Brachytherapy, Atherectomy, and Beyond$

Presentation TCT 2015

The Resurrection of Historic Therapies for Refractory Restenosis: Vascular Brachytherapy, Atherectomy, and Beyond

Presenter: Robert A. Byrne, Stefan K. James, Paul S. Teirstein

October 11, 2015

Presentation TCT 2015

Drug-Eluting Stent Restenosis State of the Art: Causes, Evaluation, and Treatment

Presenter: Robert A. Byrne, Stefan K. James, Fernando Alfonso

October 11, 2015

Presentation TCT 2015

How Was the Case Treated

Presenter: Robert A. Byrne, Stefan K. James, Ehrin J. Armstrong

October 11, 2015

Presentation TCT 2015

Case Presentation Before Treatment: An Unexpected and Difficult to Treat Stent Thrombosis

Presenter: Robert A. Byrne, Stefan K. James, Ehrin J. Armstrong

October 11, 2015

Presentation TCT 2015

Are There Differences in the Outcomes of Early, Late, and Very Late Stent Thrombosis?

Presenter: Robert A. Byrne, Stefan K. James, Donald Cutlip

October 11, 2015

Presentation TCT 2015

New Insights Into Neoatherosclerosis as a Frequent Common Denominator of DES Failure

Presenter: Robert A. Byrne, Stefan K. James, Renu Virmani

October 11, 2015

Presentation TCT 2015

Stent Thrombosis Update: Causes, Predictors, Implications, and Treatment

Presenter: Robert A. Byrne, Stefan K. James

October 11, 2015

Presentation TCT 2015

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? Yes, Eliminating the Polymer to Leave Behind a Bare-Metal Stent Surface Is a Desirable and Clinically Meaningful Goal!

Presenter: Stephen G. Ellis, John A. Ormiston, Robert A. Byrne

October 11, 2015

News Industry News

EuroPCR Late-Breaking Clinical Trials: MiStent SES® Shows Clinical Superiority over Market-Leader Xience V in Propensity Analysis at One and Three Years Post-Treatment

May 19, 2015

Presentation TCT 2014

Are There Meaningful Differences in Vascular Responses Between the Different Classes of Metallic Stent Technologies?

Presenter: Robert A. Byrne, Didier Carrié, Giuseppe De Luca, Francesco Prati

September 15, 2014

Advertisement

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Leaflet Restriction After TAVR: Two Hospitals Tracking Patients Find Similar Rates of the Phenomenon

Micell Technologies Highlights Data From Published Propensity Analysis of MiStent SES® and Market Standard Xience V® Coronary Stent

Increased Early Risk of Stent Thrombosis With the Absorb Bioresorbable Scaffold

Residual Dissection After DCB Treatment for De Novo CAD Generally Resolves

ISAR-DESIRE 4: A Prospective Randomized Trial of Plaque Modification With a Scoring Balloon During Drug-Coated Balloon Treatment of Coronary In-Stent Restenosis

ISAR-DESIRE 4: A Prospective Randomized Trial of Plaque Modification With a Scoring Balloon During Drug-Coated Balloon Treatment of Coronary In-Stent Restenosis

Plaque Modification With Scoring Balloon Improves Angiographic Outcomes In Patients Treated With A Drug-Coated Balloon For Drug-Eluting Stent Restenosis

ISAR-DESIRE 4: Scoring Balloon Predilation Effective at 1 Year in Patients With DES Restenosis

Case Presentation Before Second-Time Treatment: Recurrent DES Restenosis

The Resurrection of Historic Therapies for Refractory Restenosis: Vascular Brachytherapy, Atherectomy, and Beyond

Drug-Eluting Stent Restenosis State of the Art: Causes, Evaluation, and Treatment

How Was the Case Treated

Case Presentation Before Treatment: An Unexpected and Difficult to Treat Stent Thrombosis

Are There Differences in the Outcomes of Early, Late, and Very Late Stent Thrombosis?

New Insights Into Neoatherosclerosis as a Frequent Common Denominator of DES Failure

Stent Thrombosis Update: Causes, Predictors, Implications, and Treatment

Debate: Are Bioabsorbable Polymers Preferable to Durable Polymers for Efficacy, Safety, or Required DAPT Duration? Yes, Eliminating the Polymer to Leave Behind a Bare-Metal Stent Surface Is a Desirable and Clinically Meaningful Goal!

EuroPCR Late-Breaking Clinical Trials: MiStent SES® Shows Clinical Superiority over Market-Leader Xience V in Propensity Analysis at One and Three Years Post-Treatment

Are There Meaningful Differences in Vascular Responses Between the Different Classes of Metallic Stent Technologies?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content